Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

  • Discontinued
  • GID-TA10668
Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.